Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Conditions: Advanced cancers Institutions: The University of Texas MD Anderson Cancer Center Designed as a standard 3 + 3 study with expansion
Search Results
Eric Jonasch
Kidney Cancer, first-line options with randomized phase II evidence of benefit include the FDA-approved agents sunitinib, pazopanib, and the combination of bevacizumab and interferon. Furthermore, temsirolimus is indicated for patients with a poor
public interest and attention, Dr. Carlson reviewed the research and evidence leading to the decision for the NCCN Guidelines Panel to reaffirm its existing recommendation of bevacizumab (Avastin, Genentech/Roche) in combination with paclitaxel (Taxol
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
–Vascular Endothelial Growth Factor Therapy Perhaps no other area of breast oncology has been as controversial over the past decade as the potential role of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, in combination with
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter
regimens (eg, bevacizumab, pembrolizumab) in combination with, or as alternatives to, existing first- and second-line treatment options has led to improved outcomes in some patients. These NCCN Guidelines Insights focus on recent changes to first- and
Tayyaba Hasan
consequence of PDT,” she revealed. Overexpression of VEGF seems to contribute to the growth and metastasis of cancers. Therefore, the VEGF pathway represents a prime area for therapeutic intervention, because drugs such as bevacizumab (Avastin) may inhibit
Eric Jonasch
bevacizumab was compared with sunitinib in 950 patients in the IMmotion 151 trial. 9 Patients were stratified according to MSKCC risk score, liver metastases, and PD-L1 status. Of these, 40% were positive for PD-L1. Median PFS was 11.2 months for the
Harold J. Burstein
constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well
Nancy Kemeny
. 11. Giantonio BJ Catalano PJ Meropol NJ . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
Certain Circumstances: ∘ “Bevacizumab .... and renal cell cancer carcinoma (HLRCC)- associated RCC ” was revised.
